Kornimate/medical-research-clean huggingface dataset:
genetic variant in apolipoprotein c3 gene and fatty liver in obese children

Conditions: Fatty Liver; Obesity

Summary: in the past decades, obesity in children is much more prevalent in the world. given the increasing prevalence of pediatric obesity worldwide, fatty liver incidence is on the rise. genetic variant in apolipoprotein c3 (apoc3) gene is associated with increased liver fat content in adults. the aim of this study is to find out whether apoc3 single nucleotide polymorphism (snp) influence fatty liver in obese children and adolescent.

the primary aim of this study is to assess the associations between to investigate the association of rs2854117 c \> t and rs2854116 t \> c snps of the apoc3 gene with liver steatosis, as measured by liver ultrasound. as a secondary aim, the investigators will examine the associations between apoc3 rs2854117 c \> t and rs2854116 t \> c snps and serum alanine aminotransferase (alt) and aspartate aminotransferase (ast) levels. in addition, the investigators will further analyze the association with other biomarkers, such as body mass index, adiponectin and insulin resistance.

Eligibility criteria:
inclusion criteria: * age 6-18 years old * obesity definition: bmi \> 95% according to the age- and gender-specific standard suggested by national health institute in taiwan * willing to give written informed consent by parents exclusion criteria: * alcohol consumption * chronic liver diseases, including hepatitis b, hepatitis c, wilson disease and autoimmune hepatitis * major systemic diseases, including cardiopulmonary disease, renal failure, cancer, and psychotic disorder
role of neo-adjuvant chemotherapy in tongue preservation in locally advanced squamous cell carcinoma of oral tongue

Conditions: Tongue Neoplasms; Squamous Cell Carcinoma; Anterior Tongue Squamous Cell Carcinoma

Summary: patients enrolled for the study, who are eligible for nact, will undergo a pre-treatment workup comprising of evaluation under anesthesia (eua) for tumor mapping and tissue biopsy along with a pet-ct scan. subsequently, they would undergo 3 cycles of nact (weekly thrice) with dcf. they would be reassessed with pet-ct and eua +/- biopsy after the end of the third cycle. those who are achieving cr would undergo adjuvant ctrt. subjects who have a pr in the pet-ct scan will be re-classified based on the biopsy report. if they remain in the pr group they will undergo surgery but if the biopsy in is negative for malignancy, they will undergo adjuvant ctrt. those subjects with sd or pd would undergo surgery. subsequently, further radiation and/ or chemotherapy will be decided based on the final histopathology (of the surgical specimen) reports. pet-ct and eua +/- hpe analyses would be repeated on follow-up after 3 months of treatment completion.

patients enrolled for the study, who are eligible for neoadjuvant chemotherapy, will undergo a pre-treatment workup comprising of evaluation under anesthesia (eua) for tumor mapping and tissue biopsy along with a pet-ct scan. subsequently, they would undergo 3 cycles of neoadjuvant chemotherapy (weekly thrice) with injection docetaxel, cisplatin, and 5-fu. they would be reassessed with pet-ct and eua +/- biopsy after the end of the third cycle. those who are achieving a complete response (cr) would undergo adjuvant chemo-radiotherapy. subjects who have a partial response (pr) in the pet-ct scan will be re-classified based on the biopsy report. if they remain in the pr group they will undergo surgery. if the biopsy in these patients is negative for malignancy, they will undergo adjuvant chemoradiotherapy. those subjects with stable disease (sd) or progressive disease (pd) would undergo surgery. subsequently, further radiation and/ or chemotherapy will be decided based on the final histopathology (of the surgical specimen) reports. pet-ct and eua +/- hpe analyses would be repeated on follow-up after 3 months of treatment completion.

Eligibility criteria:
inclusion criteria: * patients of newly diagnosed squamous cell carcinoma (well/ moderately/ poorly differentiated) of oral tongue (anterior two third) presenting to health care global enterprises ltd between january 2016 to march 2017 will be included in the study. * stage iii and stage iv (t3, 4 n0-3, m 0) and selected cases of t2 with advanced nodal status will also be included in the study. exclusion criteria: * patients having recurrence/ residual disease of oral tongue. * patients who have received alternative treatments before being evaluated for nact * patient who are not fit for nact * patient not able to give consent

Keywords: neoadjuvant chemotherapy tongue malignancy squamous cell carcinoma
effect of inspiratory muscle training on physiological function and clinical outcomes after lung transplant

Conditions: Post-Lung Transplantation Bronchiectasis

Summary: the purpose of this research is to study the effect of training the inspiratory muscles (i.e. the muscle that allow you to breath-in) on exercise capacity, quality of life, and short-term clinical outcomes in patients post lung transplant.


Eligibility criteria:
inclusion criteria: - all patients who undergo single- or double-lung transplant at mayo clinic florida. exclusion criteria: * patients who do not survive the intra-operative period during the transplant surgery. * patients undergoing retransplantation. * patients undergoing multiorgan transplantation. * patients who are not willing to or who are unable to give written informed consent.

Keywords: inspiratory muscle training post lung transplant exercise capacity breathing
diet and plant sterols in the control of cholesterolemia (desco)

Conditions: Hypercholesterolemia

Summary: desco is a randomized clinical trial, controlled against placebo, performed to evaluate the effect of a phytosterol-based product (2.5 g/day), after 3 weeks of intake, on the lipid profile, also in relation to the quality of the diet, in subjects with moderate hypercholesterolemia and low / moderate global cardiovascular risk.

this is a randomized, placebo-controlled, double-blind, monocentric cross over clinical study conducted in italy. the objective of this study is to evaluate the fasting lipid profile of adults with moderate hypercholesterolemia and a low/very low cardiovascular risk, after 3 weeks of supplementation with 2.5 g/day of plant sterols, vs placebo, and to assess the relationship between the effects of the supplementation and the diet.

Eligibility criteria:
inclusion criteria: * total cholesterol plasma levels between 200 and 240 mg/dl and/or ldl cholesterol levels between 130 and 160 mg/dl * triglyceride plasma levels \<200 mg / dl * cardiovascular risk at 10 years (according to the score algorithm) \<5%. * signature of the informed consent form exclusion criteria: * subjects in secondary prevention for cardiovascular diseases or with a global cardiovascular risk (according to the score algorithm) \> 5% at 10 years * triglyceride plasma levels \>200 mg / dl * decompensated diabetes * alcoholism * food allergy * recent intake of functional foods or supplements for cholesterol control * intake of lipid-lowering drugs or drugs affecting lipid metabolism in the last 2 months * alterations in thyroid, hepatic or renal function (transaminases greater than 3 times the maximum values; glomerular filtration rate \<30ml / min), muscle diseases, even if subclinical * obesity (bmi\> 30) * any medical or surgical condition that could make the patient's adherence to the study protocol complex or inconstant.
rotator cuff repair (rcr) with and without orthoadapt augmentation

Conditions: Rotator Cuff Tear

Summary: prospective, randomized, multi-center, controlled study for patients undergoing open rotator cuff repair. patients are stratified based on tear size to one of three groups. each group is then randomized 1:1 to either repair with orthoadapt or repair without orthoadapt.


Eligibility criteria:
inclusion criteria: * ages 18-70 * mri confirmed full thickness or high grade partial thickness rotator cuff tear equal or more than 1 cm and involving the supraspinatus and/or infraspinatus tendons * tear is repairable by surgery using protocol prescribed fixation procedure * patient is able to sign and irb approved study informed consent * patient is willing and able to return for follow-up appointments and study related procedures * patient is willing to comply with prescribed physical therapy regimen exclusion criteria: * emergency, poly trauma patients * prior same shoulder surgery including rotator cuff repair except prior subacromial decompression or distal clavicle resection * shoulder pathology requiring concomitant procedures during the rotator cuff repair including labral repair, anterior or posterior stabilization, and/or capsular plication or shift * cervical spine disease * history of adhesive capsulitis in either shoulder * patient whose injury does or may involve litigation * diabetics * rotator cuff tear cannot be repaired by primary surgical means including superiorly migrated humeral head, retracted rotator cuff that cannot be mobilized to humeral head, end stage tears, rotator cuff tissue cannot retain sutures, any comorbidities that would directly or indirectly affect the reparability of the cuff * patients with grade 3 or 4 glenohumeral arthritis * patients with systemic collage disease * patients with a known hypersensitivity to equine derived materials * active or latent infection * chronic use of immunosuppressive agents * any oral or im nsaid usage within 5 days before surgery * cancer patients * decisional impaired patients * pregnant women

Keywords: rotator cuff tear rotator cuff repair
momcare: culturally relevant treatment services for perinatal depression

Conditions: Depression

Summary: the study will evaluate the effectiveness of a culturally relevant, multi-component intervention for antenatal depression. the intervention includes an engagement session, and the woman's choice of brief interpersonal psychotherapy and/or pharmacotherapy in a stepped care treatment for depression model.

the randomized control trial will evaluate the effects of a culturally relevant, multi-component intervention for antenatal depression. momcare has the potential to overcome patient, provider, and system-level barriers to care and engage depressed, low-income women in evidence-based treatments to reduce antenatal depressive symptoms, improve maternal psychosocial functioning, and ameliorate postpartum depression. specific aim 1: to evaluate the impact of momcare on treatment engagement and retention. specific aim 2: to evaluate the impact of momcare on maternal clinical symptoms and functional outcomes. specific aim 3: to conduct an incremental cost-effectiveness analysis for a health care and welfare agency perspective that includes a) tracking the medical costs of health service use in momcare and usual care patients; b) monitoring the use of infant preventative health services in both groups; and c) tracking the percentage of women on medicaid and the percentage working in both groups. the intervention will be assessed through a practical randomized controlled trial in which we have recruited 168 pregnant women with major depression and/or dysthymia who were on medicaid and/or received maternal support services (mss) in selected public health centers in seattle - king county (phskc). patients who were eligible and consented to study enrollment were randomly assigned to either usual care (uc) or momcare. baseline and four follow-up assessments (3 - 18 months post-baseline) are scheduled for study participants in both groups. the momcare intervention includes a choice of brief interpersonal psychotherapy or collaborative management of antidepressant medication. treatment response will be monitored, and the treatment will be adjusted as necessary (adding treatments, increasing dosages).

Eligibility criteria:
inclusion criteria: * 18 or older * pregnant: 12-32 weeks gestation * able to speak english * telephone access * major depressive disorder or dysthymia * on medicaid * receiving health care in king county, washington exclusion criteria: * currently in psychotherapy * currently receiving pharmacotherapy from a psychiatrist * high suicide risk * history of bipolar disorder * history of schizophrenia * substance use or dependence in previous 3 months * currently in a relationship with severe interpersonal violence * history of repetitive self-harm behavior

Keywords: depression perinatal care postpartum period pregnancy female low-income population
combination of radiation therapy and peptide specific ctl therapy in treating patients with esophageal cancer

Conditions: Esophageal Neoplasms; Esophageal Diseases; Digestive System Diseases

Summary: immunotherapy is now considered to be one of promising approaches for treating cancer. radiation therapy has been to be a cornerstone treatment for unresectable advanced esophageal cancer. radiation-induced mutation genes were identified as new sources of tumor associated antigens using exon sequencing and peptide microarray technologies. epitope peptides for these targets are able to induce peptide specific cytotoxic t lymphocytes (ctl). in this clinical trial, investigators evaluate the efficacy and safety of peptide specific ctl therapy in combination with radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer.


Eligibility criteria:
inclusion criteria: 1. patients must have unresectable, locally advanced, recurrent disease of esophageal cancer. histologically confirmed cancer of the esophagus. 2. measurable disease by ct scan 3. ecog performance status of 0 to 2 4. expected survival of at least 3months 5. laboratory values as follow: * absolute neutrophil count (anc) ≥ 1.5×109 * white blood cell count ≥ 3×109/l * platelets ≥ 100×109/l * haemoglobin (hb) ≥ 10g/dl (patients'hb should be corrected to \>10g/dl before treatment) * adequate liver function (within 1 week prior to randomization) * serum bilirubin ≤ 1.5× uln * alanine aminotransferase/aspartate transaminase (alt / ast) ≤ 2.5× uln * alkaline phosphatase (alp) ≤ 3× uln 6. able and willing to give valid written informed consent exclusion criteria: 1. pregnancy (women of childbearing potential:refusal or inability to use effective means of contraception) 2. breastfeeding 3. active or uncontrolled infection 4. prior chemotherapy, radiation therapy or immunotherapy 5. concurrent treatment with steroid or immunosuppressing agent 6. patient with peptic ulcer disease 7. other malignancy within 5 years prior to entry into the study, expect for treated non-melanoma skin cancer and cervical carcinoma in situ 8. disease to the central nervous system 9. decision of unsuitableness by principal investigator or physician-in-charge

Keywords: esophageal cancer peptide specific ctl radiation
a long-term efficacy and safety study of ixekizumab (ly2439821) in participants with active psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: the main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.


Eligibility criteria:
inclusion criteria: * presents with established diagnosis of active psoriatic arthritis (psa) for at least 6 months, and currently meets classification for psoriatic arthritis (caspar) criteria * active psa defined as the presence of at least 3 tender and at least 3 swollen joints * presence of active psoriatic skin lesion or a history of plaque psoriasis (ps) * men must agree to use a reliable method of birth control or remain abstinent during the study * women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment * have been treated with 1 or more conventional disease-modifying antirheumatic drugs (cdmards) exclusion criteria: * current or prior use of biologic agents for treatment of ps or psa * inadequate response to greater than or equal to 4 conventional disease-modifying antirheumatic drugs (dmards) * current use of more than one cdmards * diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other than psa * have received treatment with interleukin (il) -17 or il12/23 targeted monoclonal antibody (mab) therapy * serious disorder or illness other than psoriatic arthritis * serious infection within the last 3 months * breastfeeding or nursing (lactating) women

Keywords: spondyloarthritis spondylarthropathy
analysis of pregnancy-associated plasma protein-a and interleukin-6 gene polymorphisms in patients with periodontitis

Conditions: Periodontitis; Polymorphism, Restriction Fragment Length

Summary: the aim of this study is to evaluate the relationship between pregnancy associated plasma protein-a (papp-a) and interleukin-6 (il-6) gene polymorphisms and stage 3 grade b and c (s3gbc) periodontitis, and to compare periodontitis patients with healthy individuals.

a total of 226 systemically healthy subjects, consisted of 112 s3gbc periodontitis patients (p group) and 114 periodontally healthy individuals (h group) were included in our study. clinical and demographic data were recorded. genomic deoxyribonucleic acid (dna) molecules were obtained from peripheral blood. genotype for il-6 rs1800795 and papp-a rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes. the genotypic or allelic distributions of papp-a and il-6 gene polymorphisms were similar between groups (p\>0.05). our finding suggests that there is no relationship between papp-a and il-6 gene polymorphisms and s3gbc periodontitis, furthermore no difference was detected between periodontitis patients and healthy individuals regarding this gene polymorphism.

Eligibility criteria:
inclusion criteria: participants were eligible for inclusion if they were; systemically healthy non-smokers had not undergone periodontal treatment in the past 6 months had not used antibiotics or anti-inflammatory drugs in the preceding 3 months had not used any medication that could affect periodontal tissues in the past 6 months were 18 years of age or older were not pregnant, and were not lactating. exclusion criteria: the samples taken cannot be stored under appropriate conditions and are damaged. the onset of a systemic disease in a systemically healthy individual.

Keywords: polymorphism pregnancy-associated plasma protein-a interleukin-6 genetic
neovascularization patterns in corneal graft rejection

Conditions: Corneal Transplant

Summary: corneal transplantation is the most commonly performed human tissue transplant worldwide. over 40,000 corneal transplants occur in the us each year. . this study will determine specific corneal neovascularization (cn) patterns in human corneal allograft recipients to determine the characteristics that worsen the prognosis for graft survival. we will test the hypothesis that specific characteristics of cn are prognostic for corneal allograft rejection.

the investigators hope to enroll 240 subjects into the study. these patients will be enrolled prior to penetrating keratoplasty. they will be examined by the full protocol preoperatively, and postoperatively at 1 week, 1, 3, 6, 12, 18, and 24 months. during these visits slit lamp biomicroscopy will be used to study cn patterns, and take slit lamp photographs if there is any neovascularization detected, permitting us to develop algorithms of cn characteristics that are predictive for corneal allograft rejection and failure. the corneal tissue removed during these patients' surgeries will be evaluated histopathologically to identify inflammation and neovascularization to confirm and compare to what is seen clinically. there will be two short questionnaires conducted at each visit to assess stress levels.

Eligibility criteria:
inclusion criteria: * scheduled for corneal transplant exclusion criteria: * previous corneal transplant
the derivation of a clinical prediction rule to identify those with low back pain who will respond favorably to intramuscular dry-needling

Conditions: Low Back Pain

Summary: the purpose of this study is to investigate specific clinical characteristics, amongst those with low back pain, that identify patient appropriateness for intermuscular dry-needling (imdn) and to develop a prediction tool that can be used by clinicians.

the aim of the cpr is to identify patients with lbp who are likely to benefit from imdn. improvement of patient-reported outcomes and clinical measures of pain are the outcomes being predicted by the model. the cpr will be developed in a double-phase design. the first phase will be an rct, 2 x 3 group (imdn or sham) by time (pretest, post-treatment week 1, post-treatment week 2, posttest, follow-up) with repeated measures on timeframe. this design will establish if improvement of patient reported outcomes and clinical measures of pain are achieved because of the imdn treatment. furthermore, each group will receive the same type and volume of lumbar and hip stretching exercises in conjunction with their assigned needling regimen. the second phase will utilize logistic regression analysis to identify associations between the groups' demographic, historical, clinical variables and short-term pain and disability outcomes. this type of analysis will be able to identify strong predictors of the treatment outcome. various processes will be used to determine optimal model fit for analysis.

Eligibility criteria:
inclusion criteria: * males and females between the ages of 18 and 60 years with non-traumatic low back pain between the 12th rib and the buttock region. * participants must also report an oswestry disability index score of at least 20/100 points. exclusion criteria: * participants must be able to speak and read english. * individuals who are currently pregnant, currently taking pain narcotic medication or have had a prior surgery in the lumbosacral spine * those participants whose bmi is greater than 35

Keywords: low back pain dry-needling myofascial pain treatment based classification